Avalo Therapeutics (AVTX) Other financing activities (2017 - 2026)
Avalo Therapeutics' (AVTX) quarterly Other financing activities came in at $2.2 million in Q1 2026, up 5545.0% on a QoQ basis from -$40000.0 in Q4 2025.
Avalo Therapeutics (AVTX) Other financing activities (2017 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of Other financing activities data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 98.55% YoY) and the FY2022 annual result came in at $73000.0, down 80.05% from the prior year.
- Other financing activities advanced to $2.2 million in Q1 2026, from -$40000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $142.7 million in Q4 2024 to a low of -$67000.0 in Q3 2023.
- A 5-year average of $29.0 million and a median of $67000.0 in 2023 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2024 — Other financing activities jumped 11131.34% — and 2025, when it sank 100.03%.
- Tracing AVTX's Other financing activities over 5 years: stood at $48000.0 in 2022, then plunged by 239.58% to -$67000.0 in 2023, then surged by 213085.07% to $142.7 million in 2024, then tumbled by 100.03% to -$40000.0 in 2025, then soared by 5545.0% to $2.2 million in 2026.
- The last three Other financing activities figures came in at $2.2 million (Q1 2026), -$40000.0 (Q4 2025), and $40000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.23 Mn |
| Jun 30, 2026 | 5.23 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | -40,000.00 |
| Dec 31, 2025 | -40,000.00 |
| Sep 30, 2025 | 40,000.00 |
| Sep 30, 2025 | 40,000.00 |
| Dec 31, 2024 | 142.70 Mn |
| Dec 31, 2024 | 142.70 Mn |
| Jun 30, 2024 | 7.53 Mn |
| Jun 30, 2024 | 7.53 Mn |
| Mar 31, 2024 | 108.10 Mn |
| Mar 31, 2024 | 108.10 Mn |
| Sep 30, 2023 | -67,000.00 |
| Sep 30, 2023 | -67,000.00 |
| Jun 30, 2023 | 67,000.00 |
| Jun 30, 2023 | 67,000.00 |
| Dec 31, 2022 | 48,000.00 |
| Dec 31, 2022 | 48,000.00 |